Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET

Company Participants

James Markmann - Corporate Participant
Michael Rickels - Corporate Participant
Felicia Pagliuca - Corporate Participant
Susie Lisa - Senior Vice President of Investor Relations

Conference Call Participants

Adam Ferrari - JPMorgan Chase & Co, Research Division
Bryan Russell Dollinger - Leerink Partners LLC, Research Division
Dina Elmonshed - Jefferies LLC, Research Division
Jarwei Fang - Unidentified Company
Liisa Ann Bayko - Evercore ISI Institutional Equities, Research Division
Malcolm Hoffman - BMO Capital Markets Equity Research
Mohit Bansal - Wells Fargo Securities, LLC, Research Division
Terence C. Flynn - Morgan Stanley, Research Division
a division of S&P - Unidentified Company

Susie Lisa

Thanks for your patience. Good evening, everyone. My name is Susie Lisa, and I'm the Senior Vice President of Investor Relations for Vertex Pharmaceuticals. Thank you so very much for those of you joining us here in the room in Chicago at the American Diabetes Association 85th Scientific Sessions for our zimislecel update. It's an exciting day for Vertex with the update today at ADA, with the NEJM article and the summer solstice, a big day. So thank you for all of you joining us online as well.

We will be making forward-looking statements on this call. They're subject to the risks and uncertainties discussed in detail in our filings with the Securities and Exchange Commission. These statements include, without limitation, those regarding expectations for Vertex' T1D programs and actual outcomes and events could differ materially.

So here's the agenda, and we'll begin our event with our very own Felicia Pagliuca, who is the Senior Vice President of Cell and Genetic Therapy Research. She earned a PhD in biology from Cambridge University, where she was a Marshall Scholar, and did her post-doc fellowship at